NYSE · ABBV
Healthcare · Drug Manufacturers - General
$291.31
Up+$3.07 (+1.07%)
Updated Nov 8, 2026, 8:33 AM
SID Score
7.3/10
Composite research score
Smart Money
54/100
Neutral
Price performance · ABBV
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 6, 2026
ABBV closed at $291.31 after 20 trading sessions, up 3.62% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | $282.27 | $291.73 | $281.07 | $291.31 | 5.04M |
| Nov 5, 2026 | $298.735 | $302.93 | $287.71 | $288.24 | 7.97M |
| Nov 4, 2026 | $293.95 | $295.40 | $283.32 | $294.83 | 8.44M |
| Nov 3, 2026 | $288.69 | $291.322 | $284.70 | $286.00 | 5.37M |
| Nov 2, 2026 | $290.38 | $294.86 | $286.14 | $288.84 | 8.85M |
| Oct 30, 2026 | $292.00 | $298.74 | $291.01 | $294.89 | 6.9M |
| Oct 29, 2026 | $291.00 | $292.67 | $288.04 | $290.79 | 4.33M |
| Oct 28, 2026 | $282.93 | $288.80 | $281.225 | $285.99 | 3.11M |
| Oct 27, 2026 | $283.88 | $287.32 | $283.12 | $286.39 | 3.27M |
| Oct 26, 2026 | $287.05 | $289.586 | $285.18 | $286.74 | 4.52M |
| Oct 23, 2026 | $284.58 | $286.765 | $282.30 | $285.64 | 4.63M |
| Oct 22, 2026 | $284.57 | $285.76 | $278.01 | $285.19 | 6.17M |
| Oct 21, 2026 | $287.63 | $288.9999 | $282.15 | $284.80 | 4.39M |
| Oct 20, 2026 | $286.90 | $290.98 | $285.00 | $289.08 | 5.18M |
| Oct 19, 2026 | $284.23 | $287.9299 | $282.59 | $282.68 | 4.17M |
| Oct 16, 2026 | $283.61 | $286.64 | $282.955 | $285.42 | 5.78M |
| Oct 15, 2026 | $288.28 | $291.40 | $282.81 | $283.40 | 7.62M |
| Oct 14, 2026 | $277.00 | $285.3999 | $275.97 | $283.48 | 5.63M |
| Oct 13, 2026 | $283.29 | $283.43 | $273.70 | $274.36 | 6.41M |
| Oct 12, 2026 | $277.65 | $281.30 | $276.01 | $281.12 | 5.59M |
The latest Smart Investors Daily articles mentioning ABBV.
Company
Market Activity
Research & News
ABBV research
Company profile and research snapshot.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 2, 2026 | Guggenheim | Buy | — |
| Nov 2, 2026 | Wells Fargo | Overweight | — |
| Nov 2, 2026 | RBC Capital | Outperform | — |
| Nov 2, 2026 | Canaccord Genuity | Buy | — |
| Nov 2, 2026 | Cantor Fitzgerald | Overweight | — |
Generated Nov 7, 2026, 9:00 PM
AbbVie gained 1.07% today as the pharmaceutical giant continues to attract investor attention as a defensive healthcare play and high-yield dividend stock. The modest uptick reflects broader market recognition of ABBV's strategic positioning, though no major company-specific catalyst emerged today.
Bottom line: AbbVie's modest 1.07% gain reflects its status as a defensive, high-yield healthcare stock gaining traction with income-oriented investors amid market uncertainty. While the company's R&D investments and attractive valuation are positives, investors should monitor pipeline progress and dividend sustainability as key metrics for long-term returns.
Yahoo · Nov 7, 2026
Quitting at 58 sounds simple when your savings sit in a Roth. But one hidden clock, and the wrong conversion pulled at the wrong time, can turn tax-free money into a penalty bill. Find out which dates to check before you walk out.
Yahoo · Nov 7, 2026
AbbVie (NYSE: ABBV) agreed a global licensing deal with Nxera Pharma for an oral EP4 receptor agonist targeting inflammatory bowel disease worth up to US$1.37b. The agreement gives AbbVie worldwide rights to develop and commercialize Nxera's EP4 candidate, while Nxera retains certain co funding and royalty interests. AbbVie is expanding its UK research presence with a new Oxford facility focused on immunology, neuroscience, and oncology programs. The Nxera inflammatory bowel disease...
Yahoo · Nov 7, 2026
Pfizer offers a higher dividend yield and a cheaper valuation, while AbbVie brings stronger earnings momentum and a history of dividend growth.
Yahoo · Nov 6, 2026
Key TakeawaysAbbVie raised its quarterly dividend 5. 2% to $1.
Interpretive context generated from the platform’s current data sources.
AbbVie Inc. shares traded at $291.31, reflecting a single-day decline of 1.32% per SID market data. Despite the session's pullback, the stock has demonstrated sustained upward momentum across multiple timeframes, gaining 6.93% over the past month, 17.48% over three months, and 32.37% over the trailing twelve months. The stock currently trades well above key moving averages, sitting 7.12% above its 50-day moving average of $271.95 and 21.68% above its 200-day moving average of $239.39, according to SID market data. The 14-day RSI registers at 58.7, indicating neither overbought nor oversold conditions. AbbVie carries a beta of 0.334, reflecting significantly lower volatility relative to the broader market. Average daily trading volume stands at approximately 6.4 million shares, supporting the stock's current market capitalization of roughly $410.1 billion, positioning it among the largest healthcare companies globally.
AbbVie Inc. currently trades at a trailing price-to-earnings ratio of 97.75, a notably elevated multiple that reflects the earnings impact of significant acquisition-related amortization and one-time charges, per SID market data. The PEG ratio stands at 1.25, suggesting the stock's premium valuation is partially supported by projected earnings growth. The company's price-to-book ratio registers as negative at -126.33, a direct consequence of AbbVie's negative book value driven by accumulated goodwill impairments and substantial debt incurred through its acquisition strategy, according to SEC filings. Offsetting these stretched valuation metrics, AbbVie maintains a dividend yield of 2.87%, providing meaningful income return to shareholders. Within the healthcare sector, AbbVie's elevated P/E reflects its transitional phase as it pivots revenue streams from legacy Humira toward newer immunology and oncology franchises, with forward earnings expectations anticipated to compress the trailing multiple significantly.
AbbVie Inc. registers a composite smart money score of 54 out of 100, reflecting a neutral overall signal per SID market data. The institutional component scores a perfect 25 out of 25, indicating robust and sustained institutional ownership and accumulation among major fund managers, according to 13F institutional filings. Insider activity scores a strong 18 out of 25, supported by two insider purchases and zero insider sales over the past 90 days, per SEC Form 4 filings. The absence of any insider selling alongside multiple buys suggests internal confidence in the company's forward trajectory. Dark pool activity scores a modest 9.4 out of 25, indicating relatively subdued off-exchange trading volume. Congressional trading activity registers at just 1.6 out of 25, showing minimal recent positioning by members of Congress. The divergence between exceptionally strong institutional conviction and more muted dark pool and congressional activity creates the neutral composite reading, though the insider buying pattern provides a constructive directional signal within the smart money framework.
AbbVie Inc.'s recent earnings trajectory shows mixed results relative to consensus expectations, according to company earnings reports. In the most recent reported quarter, the company delivered earnings per share of $3.82 against an estimate of $3.77, representing a positive surprise of $0.05. However, the prior quarter saw a miss, with actual EPS of $3.65 falling short of the $3.77 estimate by $0.12. The quarter before that produced a near-inline result, with $2.65 actual EPS versus $2.66 estimated, a marginal miss of $0.01. Looking ahead, analysts project EPS of $3.01 for the upcoming reporting period, per analyst estimates. The sequential earnings pattern reflects the cadence of AbbVie's product portfolio transition, with quarterly variability driven by Humira biosimilar erosion offset by growth in Skyrizi and Rinvoq. The company's ability to consistently meet or exceed the $3.01 consensus will serve as a key barometer of its diversification progress.
Wall Street consensus on AbbVie Inc. remains uniformly constructive, with all five most recent analyst actions reaffirming bullish ratings, per Wall Street analyst reports. On November 2, 2026, Guggenheim maintained its Buy rating, while Wells Fargo reiterated its Overweight designation, according to SID consensus data. RBC Capital simultaneously maintained its Outperform rating, and Canaccord Genuity reaffirmed its Buy recommendation. Cantor Fitzgerald also sustained its Overweight stance on the same date. Notably, none of the five analysts altered their prior ratings, signaling entrenched conviction rather than reactionary upgrades. The synchronized timing of these reaffirmations suggests the actions followed a material company event, likely the quarterly earnings release. The absence of any Hold, Underweight, or Sell ratings among recent coverage updates underscores broad institutional confidence in AbbVie's commercial execution and pipeline trajectory. The unanimously positive analyst posture aligns with the stock's 32.37% trailing twelve-month gain and strong institutional ownership scores.
The latest Smart Investors Daily articles mentioning ABBV.
